Anja Schweizer
Overview
Explore the profile of Anja Schweizer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
1281
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chyou J, Tay W, Tromp J, Ouwerkerk W, Yiu K, Cleland J, et al.
JACC Heart Fail
. 2025 Feb;
13(3):453-464.
PMID: 39918534
Background: Atrial fibrillation (AF) and heart failure (HF) each contributes to global disease burden and can coexist. The interplay of prior HF, prior AF, and presenting rhythm have not previously...
2.
Tay W, Teng T, Ouwerkerk W, Angermann C, Dickstein K, Cleland J, et al.
EClinicalMedicine
. 2025 Jan;
80:103031.
PMID: 39877260
Background: Heart Failure (HF) quality of care (QoC) is associated with clinical outcomes. Therefore, we investigated differences in HF QoC across worldwide regions (with differing national income) and the association...
3.
Bistola V, Farmakis D, Tromp J, Tay W, Ouwerkerk W, Angermann C, et al.
JACC Heart Fail
. 2024 Nov;
13(2):229-247.
PMID: 39520445
Background: Outcomes of hospitalized patients with heart failure (HF) and characteristics of advanced HF stage may vary across left ventricular ejection fraction (LVEF) and world regions. Objectives: This study sought...
4.
Gerhardt T, Gerhardt L, Ouwerkerk W, Roth G, Dickstein K, Collins S, et al.
Lancet Glob Health
. 2023 Nov;
11(12):e1874-e1884.
PMID: 37973338
Background: Multimorbidity (two or more comorbidities) is common among patients with acute heart failure, but comprehensive global information on its prevalence and clinical consequences across different world regions and income...
5.
Tromp J, Ezekowitz J, Ouwerkerk W, Chandramouli C, Yiu K, Angermann C, et al.
JACC Heart Fail
. 2023 Sep;
11(9):1262-1271.
PMID: 37678961
Background: Previous reports suggest that risk factors, management, and outcomes of acute heart failure (AHF) may differ by sex, but they rarely extended analysis to low- and middle-income countries. Objectives:...
6.
Farmakis D, Tromp J, Marinaki S, Ouwerkerk W, Angermann C, Bistola V, et al.
Eur J Heart Fail
. 2023 Mar;
25(6):818-828.
PMID: 36974770
Aim: Evidence on healthcare resource utilization (HCRU) for hospitalized patients with heart failure (HF) and reduced (HFrEF), mildly reduced (HFmrEF) and preserved (HFpEF) ejection fraction is limited. Methods And Results:...
7.
Ouwerkerk W, Tromp J, Cleland J, Angermann C, Dahlstrom U, Ertl G, et al.
Eur J Heart Fail
. 2022 Oct;
25(1):43-51.
PMID: 36196060
Aim: Acute heart failure can be a life-threatening medical condition. Delaying administration of intravenous furosemide (time-to-diuretics) has been postulated to increase mortality, but prior reports have been inconclusive. We aimed...
8.
McNaughton C, McConnachie A, Cleland J, Spertus J, Angermann C, Duklas P, et al.
Eur J Heart Fail
. 2022 Apr;
24(6):1020-1029.
PMID: 35429091
Aims: Recovery of well-being after hospitalisation for acute heart failure (AHF) is a measure of the success of interventions and the quality of care but has rarely been quantified. Accordingly,...
9.
Tromp J, Ouwerkerk W, Teng T, Cleland J, Bamadhaj S, Angermann C, et al.
Eur Heart J
. 2022 Apr;
43(23):2224-2234.
PMID: 35393622
Background: Heart failure (HF) is a global challenge, with lower- and middle-income countries (LMICs) carrying a large share of the burden. Treatment for HF with reduced ejection fraction (HFrEF) improves...
10.
Reijman M, Schweizer A, Peterson A, Bruckert E, Stratz C, Defesche J, et al.
Eur J Prev Cardiol
. 2022 Feb;
29(9):1361-1368.
PMID: 35175352
Background: Inclisiran is a small interfering RNA molecule that reduces low-density lipoprotein cholesterol (LDL-C) by inhibition of proprotein convertase subtilisin/kexin type 9. This subcutaneous, twice-yearly administered agent has been shown...